Nurix Therapeutics, Inc. SEC Filings

Nurix Therapeutics announced an underwritten public offering, agreeing to issue and sell 24,485,799 shares of common stock at an offering price of $10.21 per share. The company estimates net proceeds of approximately $234.3 million after underwriting discounts, commissions, and expenses.

Nurix plans to use the proceeds primarily to fund clinical development of its drug candidates, including the clinical development of bexobrutideg in chronic lymphocytic leukemia and for potential autoimmune indications, as well as broader R&D, working capital, and general corporate purposes. The offering is being conducted under the company’s shelf registration statement on Form S-3 and a related prospectus supplement, with J.P. Morgan, Jefferies, and Stifel acting as representatives of the underwriters.

Nurix Therapeutics (NRIX) announced initiation of the DAYBreak Phase 2 trial of bexobrutideg (NX-5948), a pivotal single-arm study in relapsed/refractory CLL/SLL. The study will enroll approximately 100 patients whose disease progressed after a covalent BTK inhibitor, a non-covalent BTK inhibitor, and a BCL-2 inhibitor. The primary endpoint is objective response rate per iwCLL criteria assessed by an independent review committee, and the first site was activated in October 2025.

The company selected a 600 mg once-daily dose based on Phase 1b data and alignment with U.S., U.K., and EU regulators, and plans a global randomized Phase 3 confirmatory trial in the first half of 2026 with ~400 patients comparing bexobrutideg to investigator’s choice regimens. Nurix also reported Phase 1a data for NX-1607 in solid tumors, with a disease control rate of 49.3% among 71 evaluable patients as of July 26, 2025, including a confirmed partial response in MSS colorectal cancer and a tolerable safety profile.

Nurix Therapeutics (NRIX) is a clinical-stage company focused on targeted protein degradation with partnered discovery programs and wholly owned BTK and CBL-B programs. For the nine months ended August 31, 2025 the company reported a net loss of $186.2M and an accumulated deficit of $925.0M. Cash, cash equivalents and marketable securities were $428.8M, which management expects is sufficient to fund operations for at least the next 12 months.

Collaboration and license activity remain a primary source of revenue: license revenue of $30.0M was recognized in the nine months ended August 31, 2025, and deferred revenue balances were $5.5M (Gilead), $35.7M (Pfizer) and $0 (Sanofi) as of August 31, 2025. The company expects substantial additional funding will be required beyond 12 months to complete clinical development and commercialization efforts and may pursue equity, debt or partnership financing.

Nurix Therapeutics director Julia P. Gregory reported a transaction on 09/17/2025 showing acquisition of 10,750 shares of common stock. The filing indicates a director stock option with an exercise/conversion price of $1.86 was exercised (transaction code M), resulting in 10,750 shares acquired and 10,750 shares owned following the transaction. The option covers the right to buy 10,750 shares and lists an expiration date of 12/22/2029. The filing notes the option vested monthly beginning September 12, 2019 and fully vested on August 12, 2023.

Nurix Therapeutics reported a board committee leadership change following the resignation of Dr. Kunkel. The board appointed Roy D. Baynes, MB.Bch., M.Med., Ph.D., who is already a board member and a member of the Clinical and Commercialization Committee, to serve as chair of that committee effective September 1, 2025. The change is administrative and focused on committee leadership; no financial data, transactions, or other operational actions are disclosed in the filing.